Hamilton Thorne Ltd. is a public company traded on the Toronto Venture Exchange (TSXV:HTL).
We are a leading global provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets.
Over thirty years ago, we started as a small business serving the animal breeding market and began our vision for providing the most innovative tools for the fertility industry. As In Vitro Fertilization (IVF) moved from an experimental procedure to a mainstream treatment for human infertility, we expanded as well.
Commencing in 2015, we began accelerating our growth by completing the acquisition of the OosightTM product line from Perkin Elmer (2015), Embryotech Laboratories (2016) and Gynemed & Co GmbH (2017).
As we have expanded to become a rapidly growing business, we remain focused on our customers and committed to creating products and services that support improved outcomes and scientific breakthroughs in their field.
Today, our products and services are provided to a diverse customer base from in vitro fertilization clinics and pharmaceutical companies to animal research facilities and academic establishments worldwide.
To improve fertility results by delivering the most innovative Assisted Reproductive Technologies products and services to the human clinical, animal breeding and related research markets.
Building Quality and Trust
At Hamilton Thorne we focus on quality and safety to build trust in our products. Rigorous internal quality auditing maintains the highest level of production and quality control standards. We follow strict ISO guidelines and comply with applicable regulations to ensure reliability in every product.
We believe in creating Innovations to Rely On.